RU2015146418A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2015146418A3 RU2015146418A3 RU2015146418A RU2015146418A RU2015146418A3 RU 2015146418 A3 RU2015146418 A3 RU 2015146418A3 RU 2015146418 A RU2015146418 A RU 2015146418A RU 2015146418 A RU2015146418 A RU 2015146418A RU 2015146418 A3 RU2015146418 A3 RU 2015146418A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361815043P | 2013-04-23 | 2013-04-23 | |
| US61/815,043 | 2013-04-23 | ||
| PCT/EP2014/058251 WO2014173959A2 (en) | 2013-04-23 | 2014-04-23 | Synthetic library of specific binding molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015146418A RU2015146418A (ru) | 2017-05-26 |
| RU2015146418A3 true RU2015146418A3 (https=) | 2018-05-07 |
Family
ID=50543598
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015146418A RU2015146418A (ru) | 2013-04-23 | 2014-04-23 | Библиотека синтетических специфически связывающих молекул |
| RU2015146419A RU2015146419A (ru) | 2013-04-23 | 2014-04-23 | Выделение терапевтических доменов vnar, специфичных по отношению к мишени icosl |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015146419A RU2015146419A (ru) | 2013-04-23 | 2014-04-23 | Выделение терапевтических доменов vnar, специфичных по отношению к мишени icosl |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10472410B2 (https=) |
| EP (3) | EP3683312B1 (https=) |
| JP (2) | JP6616284B2 (https=) |
| KR (2) | KR20160010466A (https=) |
| CN (2) | CN105531370A (https=) |
| AU (3) | AU2014257549B2 (https=) |
| BR (2) | BR112015026729A2 (https=) |
| CA (2) | CA2909921C (https=) |
| DK (1) | DK2989203T3 (https=) |
| RU (2) | RU2015146418A (https=) |
| WO (2) | WO2014173959A2 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4151658A1 (en) | 2012-05-07 | 2023-03-22 | Elasmogen Limited | Single domain binding molecule |
| JP6616284B2 (ja) | 2013-04-23 | 2019-12-04 | ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン | 特異的結合分子の人工ライブラリー |
| EP3160995A2 (en) | 2014-06-26 | 2017-05-03 | Ossianix Inc. | Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds |
| EP3215531A1 (en) * | 2014-11-03 | 2017-09-13 | Merck Patent GmbH | Methods for generating bispecific shark variable antibody domains and use thereof |
| EP3218411B1 (en) | 2014-11-14 | 2022-01-12 | Ossianix, Inc. | Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use |
| ITUB20151014A1 (it) * | 2015-05-27 | 2016-11-27 | Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro | Ligandi del recettore b7h nel trattamento di osteopenia e osteoporosi |
| MX2018012472A (es) | 2016-04-15 | 2019-08-12 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras variantes de ligando icos y sus usos. |
| CN107130300A (zh) * | 2016-10-08 | 2017-09-05 | 深圳劲宇生物科技有限公司 | 一种dna编码分子库的合成方法及dna模板 |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US11919949B2 (en) | 2017-09-27 | 2024-03-05 | Elasmogen Ltd | Specific binding molecules |
| US11180544B2 (en) * | 2017-11-07 | 2021-11-23 | City University Of Hong Kong | Method of producing antibody fragment |
| GB201721802D0 (en) | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
| WO2020056327A1 (en) | 2018-09-14 | 2020-03-19 | Ossianix, Inc. | Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers |
| CN111197074B (zh) * | 2018-11-20 | 2023-08-15 | 深圳华大生命科学研究院 | 条纹斑竹鲨免疫球蛋白新抗原受体可变区库引物及应用 |
| WO2020167872A1 (en) * | 2019-02-11 | 2020-08-20 | Woodbury Neal W | Systems, methods, and media for molecule design using machine learning mechanisms |
| GB201906997D0 (en) * | 2019-05-17 | 2019-07-03 | Elasmogen Ltd | Conjugates |
| GB201908886D0 (en) * | 2019-06-20 | 2019-08-07 | Almac Discovery Ltd | Anthracycline derivatives |
| CN116457368A (zh) * | 2020-05-01 | 2023-07-18 | 匹兹堡大学联邦高等教育系统 | 用于鉴定纳米抗体和纳米抗体亲和力的组合物和方法 |
| CN112301431B (zh) * | 2020-08-12 | 2023-01-31 | 华东理工大学 | 基于鲨鱼抗体可变区v-nar的噬菌体文库及其构建方法 |
| GB202020154D0 (en) * | 2020-12-18 | 2021-02-03 | Almac Discovery Ltd | ROR1-specific variant antigen binding molecules |
| GB202020152D0 (en) | 2020-12-18 | 2021-02-03 | Elasmogen Ltd | Fast-track humanisation of specific binding molecules |
| WO2022212429A1 (en) * | 2021-03-31 | 2022-10-06 | Sachdev Sidhu | Anti-viral compositions for rift valley fever virus infections and methods of using same |
| EP4141028A1 (en) | 2021-08-31 | 2023-03-01 | Johann-Wolfgang-Goethe-Universität Frankfurt am Main | Personalized vnar-based chimeric antigen receptors (vnar-car) for the treatment of clonal b-and t cell malignancies, and methods for producing vnar-cars |
| GB202407865D0 (en) | 2024-06-03 | 2024-07-17 | Elasmogen Ltd | Self immolative compounds |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0008419D0 (en) * | 2000-04-05 | 2000-05-24 | Bioinvent Int Ab | A method for invitro molecular evolution of antibody function |
| PT1419179E (pt) | 2001-08-10 | 2010-03-16 | Univ Aberdeen | Domínios de ligação de antigenes |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| EP2272566A3 (en) | 2003-08-18 | 2013-01-02 | MedImmune, LLC | Humanisation of antibodies |
| US20050053989A1 (en) * | 2003-08-27 | 2005-03-10 | Gil Sharon | Libraries of recombinant chimeric proteins |
| JP2008511286A (ja) | 2004-06-02 | 2008-04-17 | ダイアテック・ピーティワイ・リミテッド | サメ類のＩｇＮＡＲドメインに基づく結合成分 |
| CA2569509C (en) * | 2004-06-03 | 2014-08-12 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| WO2006003999A1 (ja) * | 2004-07-05 | 2006-01-12 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | ヒト抗ヒトb7rp-1抗体およびその抗体フラグメント |
| CA2602035C (en) * | 2005-03-18 | 2015-06-16 | Medimmune, Inc. | Framework-shuffling of antibodies |
| JP5171611B2 (ja) | 2005-03-25 | 2013-03-27 | ナショナル リサーチ カウンシル オブ カナダ | 可溶性ポリペプチドの単離方法 |
| US8188223B2 (en) | 2005-05-18 | 2012-05-29 | Ablynx N.V. | Serum albumin binding proteins |
| EP2397498A3 (en) | 2005-07-18 | 2013-11-27 | Amgen, Inc | Human anti-B7RP1 neutralizing antibodies |
| AU2007293614A1 (en) | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| ATE536369T1 (de) | 2006-10-11 | 2011-12-15 | Ablynx Nv | Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung |
| WO2009026638A1 (en) | 2007-08-31 | 2009-03-05 | Melbourne Health | Marine-animal derived therapeutic and diagnostic agents for hepatitis b |
| AU2009301631A1 (en) | 2008-10-06 | 2010-04-15 | Commonwealth Scientific And Industrial Research Organisation | Amyloid-beta peptide crystal structure |
| WO2010040174A1 (en) * | 2008-10-07 | 2010-04-15 | Zap Holdings Pty Ltd | Synchronization of relational databases with olap cubes |
| WO2011056056A2 (es) | 2009-11-04 | 2011-05-12 | Laboratorios Silanes, S.A. De C.V. | Dominios vhnar anti -citocinas |
| EP2646461A2 (en) | 2010-12-03 | 2013-10-09 | Cyclogenix Ltd | VARIANTS OF igNAR |
| EP4151658A1 (en) * | 2012-05-07 | 2023-03-22 | Elasmogen Limited | Single domain binding molecule |
| CN103031304A (zh) * | 2012-12-27 | 2013-04-10 | 苏州大学 | 一种微小rna用于调控b7-h2基因表达 |
| JP6616284B2 (ja) | 2013-04-23 | 2019-12-04 | ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン | 特異的結合分子の人工ライブラリー |
-
2014
- 2014-04-23 JP JP2016509450A patent/JP6616284B2/ja active Active
- 2014-04-23 EP EP19208141.2A patent/EP3683312B1/en active Active
- 2014-04-23 CA CA2909921A patent/CA2909921C/en active Active
- 2014-04-23 WO PCT/EP2014/058251 patent/WO2014173959A2/en not_active Ceased
- 2014-04-23 US US14/785,975 patent/US10472410B2/en active Active
- 2014-04-23 JP JP2016509455A patent/JP6591964B2/ja active Active
- 2014-04-23 EP EP14718999.7A patent/EP2989203B1/en active Active
- 2014-04-23 CN CN201480035842.9A patent/CN105531370A/zh active Pending
- 2014-04-23 DK DK14718999.7T patent/DK2989203T3/da active
- 2014-04-23 WO PCT/EP2014/058276 patent/WO2014173975A1/en not_active Ceased
- 2014-04-23 RU RU2015146418A patent/RU2015146418A/ru not_active Application Discontinuation
- 2014-04-23 US US14/786,074 patent/US10202438B2/en active Active
- 2014-04-23 EP EP14720559.5A patent/EP2989204B1/en active Active
- 2014-04-23 CN CN201480035865.XA patent/CN105492610B/zh active Active
- 2014-04-23 AU AU2014257549A patent/AU2014257549B2/en active Active
- 2014-04-23 CA CA2909923A patent/CA2909923A1/en not_active Abandoned
- 2014-04-23 AU AU2014257565A patent/AU2014257565A1/en not_active Abandoned
- 2014-04-23 RU RU2015146419A patent/RU2015146419A/ru not_active Application Discontinuation
- 2014-04-23 KR KR1020157033307A patent/KR20160010466A/ko not_active Withdrawn
- 2014-04-23 KR KR1020157033430A patent/KR102320189B1/ko active Active
- 2014-04-23 BR BR112015026729A patent/BR112015026729A2/pt not_active Application Discontinuation
- 2014-04-23 BR BR112015026716A patent/BR112015026716A2/pt not_active IP Right Cessation
-
2019
- 2019-02-11 US US16/271,959 patent/US11459377B2/en active Active
- 2019-07-18 AU AU2019206064A patent/AU2019206064A1/en not_active Abandoned
Also Published As
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180822 |